14.96
+1.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Korro Bio
From its filings with the US Securities and Exchange Commission
Korro Bio is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KRRO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $6.4m and a net loss of $117.3m. At that date it held total assets of $113.5m and shareholders' equity of $51.4m.
We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient change to a single nucleoside (adenosine to an inosine edit). By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. We use an oligonucleotide-based approach and expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, including N-acetylgalactosamine, or GalNAc, -conjugated delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. However, the scientific evidence to support the feasibility of developing lead candidates using our RNA editing technology is both preliminary and limited. Moreover, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and limited clinical data has been generated to date.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Oct 2019
- Employees
- 58
- Website
- korrobio.com ↗
- Head office
- 60 FIRST STREET, CAMBRIDGE, MA, 02141
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Nessan BerminghamIndependent Chairman of the Board$237,478
- Dr. Ram AiyarPresident, Chief Executive Officer, Director, since 2023$939,075
- Mr. Vineet AgarwalChief Financial Officer$1.3m
- Mr. Todd ChappellChief Operating Officer
- Dr. Jeffrey CerioSenior Vice President, General Counsel, Corporate Secretary$1.5m
- Ms. Stephanie EngelsSenior Vice President - People and Culture
- Mr. Venkat KrishnamurthySenior Vice President - Platform
- Dr. Gaozhong ZhuSenior Vice President of Chemistry, Manufacturing and Controls
- Mr. Oliver DolanPrincipal Accounting Officer
- Dr. Loic VincentChief Scientific Officer
- Dr. Kemi OlugemoChief Medical Officer$2.7m
- Dr. Ali BehbahaniIndependent Director$202,978
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 33
- Social
- 64
- Governance
- 5
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Korro Bio Inc's OPERA platform enables precise RNA editing for rare and prevalent diseases.
- The company focuses on liver and central nervous system treatments with its RNA editing technology.
- Korro Bio employs 48 full-time employees in Cambridge, Massachusetts.
Weaknesses
- Korro Bio's IPO was on 3 October 2019, which may limit recent financial data availability.
- The company has only 48 employees, indicating a small operational scale.
- Korro Bio operates in the Biotechnology sector with limited market presence.
Opportunities
- Korro Bio's RNA editing technology could expand into new therapeutic areas beyond liver and CNS.
- The growing biopharmaceutical market offers opportunities for RNA editing applications.
- Korro Bio's focus on genetic medicines aligns with increasing healthcare innovation trends.
Threats
- Korro Bio faces competition from established biotech firms in the RNA editing space.
- Regulatory challenges may impact the development of RNA-based therapies.
- The biotechnology sector is highly competitive with rapid technological changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.